Winch Advisory Services’s Axsome Therapeutics AXSM Stock Holding History

Winch Advisory Services’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-300	Closed	-$2K	–	307
2017 Q4	$2K	Buy	+300	New	+$1.51K	﹤0.01%	255
2017 Q3	–	Sell	-300	Closed	-$2K	–	293
2017 Q2	$2K	Buy	+300	New	+$1.26K	﹤0.01%	263

Other funds holding AXSM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

OPPM

Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Winch Advisory Services's AXSM Position: Q1 2018 in Review

Winch Advisory Services sold out of Axsome Therapeutics (AXSM) in Q1 2018, closing a stake of 300 shares — an estimated $2K sold.

Winch Advisory Services first reported a position in AXSM in Q2 2017 and held it in 2 quarters. The position peaked at $2K in Q4 2017. 36 funds tracked by Wall St. Rank hold AXSM as of Q1 2018.

Winch Advisory Services reported no remaining Axsome Therapeutics position as of Q1 2018 after selling out during the quarter.
Winch Advisory Services sold 300 Axsome Therapeutics shares in Q1 2018, an estimated $2K.
Winch Advisory Services first reported a position in Axsome Therapeutics in Q2 2017 and held it in 2 quarters.
Winch Advisory Services's Axsome Therapeutics position peaked at $2K in Q4 2017.
36 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2018.

Based on Winch Advisory Services's 13F filing for Q1 2018, filed 11 May 2018.